Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine Academic Article uri icon

Overview

MeSH Major

  • Anthracyclines
  • Antibiotics, Antineoplastic
  • Breast Neoplasms
  • Deoxycytidine
  • Drug Resistance, Neoplasm
  • Epothilones
  • Fluorouracil
  • Taxoids

abstract

  • Ixabepilone demonstrated clear activity and a manageable safety profile in patients with MBC resistant to anthracycline, taxane, and capecitabine. Responses were durable and notable in patients who had not previously responded to multiple prior therapies.

publication date

  • August 10, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.09.3849

PubMed ID

  • 17606974

Additional Document Info

start page

  • 3407

end page

  • 14

volume

  • 25

number

  • 23